{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:45:18Z","timestamp":1789181118246,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.therap.2022.01.018","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T21:22:14Z","timestamp":1643923334000},"page":"603-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Suivi th\u00e9rapeutique pharmacologique de la cyam\u00e9mazine\u00a0: comment interpr\u00e9ter une concentration\u00a0? Une revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"77","author":[{"given":"Hugo","family":"Alarcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Chachia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Saint-Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Couderc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.01.018_bib0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1527-3458.2004.tb00023.x","article-title":"Preclinical and clinical pharmacology of cyamemazine\u00a0: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome","volume":"10","author":"Bourin","year":"2004","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.therap.2022.01.018_bib0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.encep.2008.03.007","article-title":"Prescribing patterns of antipsychotics in 13\u00a0French psychiatric hospitals","volume":"35","author":"Bret","year":"2009","journal-title":"Encephale"},{"key":"10.1016\/j.therap.2022.01.018_bib0175","series-title":"Open Medic: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments en 2020. L\u2019Assurance maladie","year":"2021"},{"key":"10.1016\/j.therap.2022.01.018_bib0180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.therap.2016.11.045","article-title":"Pr\u00e9valence de l\u2019usage des antipsychotiques dans une cohorte de patients suivis dans un centre de soins, de pr\u00e9vention et d\u2019accompagnement en addictologie (CSAPA)","volume":"72","author":"Peyri\u00e8re","year":"2017","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2022.01.018_bib0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"1\u201302","key":"10.1016\/j.therap.2022.01.018_bib0190","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2022.01.018_bib0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2007.09.025","article-title":"Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes","volume":"578","author":"Benyamina","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.therap.2022.01.018_bib0200","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0006-2952(02)01515-0","article-title":"Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes","volume":"65","author":"Hameg","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.therap.2022.01.018_bib0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.psychres.2012.01.009","article-title":"Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal","volume":"198","author":"Benyamina","year":"2012","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.therap.2022.01.018_bib0210","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S2590-2415(19)30354-X","article-title":"Existe-t-il un pouvoir addictog\u00e8ne de la cyamemazine\u00a0? R\u00e9flexions autour de cas cliniques","volume":"1","author":"Le Marie","year":"2018","journal-title":"Fr J Psychiatry"},{"key":"10.1016\/j.therap.2022.01.018_bib0215","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.therap.2016.07.004","article-title":"le r\u00e9seau fran\u00e7ais des centres r\u00e9gionaux de pharmacovigilance. Cyamemazine (Tercian\u00ae): Exploration of extrapyramidal syndrome cases contained in the French pharmacovigilance database","volume":"72","author":"Khouri","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.01.018_bib0220","unstructured":"ANSM. Tercian. 2012. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0213724.htm.[Consult\u00e9 le 31\u00a0janvier 2022]."},{"key":"10.1016\/j.therap.2022.01.018_bib0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.therap.2016.12.010","article-title":"The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings","volume":"72","author":"Briet","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.01.018_bib0230","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S2590-2415(19)30251-X","article-title":"Les effets anticholinergiques en psychiatrie: on conna\u00eet, mais on s\u2019adapte comment\u00a0?","volume":"1","author":"Javelot","year":"2018","journal-title":"Fr J Psychiatry"},{"key":"10.1016\/j.therap.2022.01.018_bib0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejps.2007.09.003","article-title":"Characterization of human cytochrome P450\u00a0enzymes involved in the metabolism of cyamemazine","volume":"32","author":"Arbus","year":"2007","journal-title":"Eur J Pharm"},{"key":"10.1016\/j.therap.2022.01.018_bib0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-011-2289-1","article-title":"Active cyamemazine metabolites in patients treated with cyamemazine (Tercian\u00ae): influence on cerebral dopamine D2\u00a0and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET)","volume":"217","author":"Hod\u00e9","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2022.01.018_bib0245","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jat\/17.6.386","article-title":"Toxicological data in a fatality involving cyamemazine","volume":"17","author":"Tracqui","year":"1993","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.therap.2022.01.018_bib0250","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/jat\/25.5.348","article-title":"Concentrations of cis(Z)-clopenthixol and trans(E)-clopenthixol in a lethal case involving zuclopenthixol, diazepam, and cyamemazine","volume":"25","author":"Rop","year":"2001","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.therap.2022.01.018_bib0255","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jflm.2018.01.001","article-title":"Repeated attempted homicide by administration of drugs documented by hair analysis","volume":"54","author":"Baillif-Couniou","year":"2018","journal-title":"J Forensic Leg Med"},{"issue":"1","key":"10.1016\/j.therap.2022.01.018_bib0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0379-0738(03)00260-3","article-title":"Acute fatal poisoning with cyamemazine","volume":"137","author":"Alunni-Perret","year":"2003","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2022.01.018_bib0265","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00213-005-2172-z","article-title":"A positron emission tomography (PET) study of cerebral dopamine D2\u00a0and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian)","volume":"180","author":"Hod\u00e9","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2022.01.018_bib0270","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/pds.1801","article-title":"Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database","volume":"18","author":"Peyri\u00e8re","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2022.01.018_bib0275","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00042737-199904000-00016","article-title":"Cyamamezine-induced acute hepatitis after unique massive intake: a case report","volume":"11","author":"Cadranel","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.therap.2022.01.018_bib0280","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jat\/bkaa100","article-title":"Identification and quantification of antipsychotics in blood samples by LC-MS-MS: case reports and data from three years of routine analysis","volume":"44","author":"Proen\u00e7a","year":"2020","journal-title":"J Anal Toxicol"},{"issue":"3","key":"10.1016\/j.therap.2022.01.018_bib0285","first-page":"47","article-title":"Recherche et dosage de cyam\u00e9mazine et de ses metabolites dans les liquides biologiques apr\u00e8s une intoxication mortelle","volume":"VI","author":"Ghysel","year":"1994","journal-title":"Toxicorama"},{"key":"10.1016\/j.therap.2022.01.018_bib0290","first-page":"306","article-title":"Intoxication mortelle par cyam\u00e9mazine","volume":"11","author":"Darmanaden","year":"1992","journal-title":"J Pharm Clin"},{"key":"10.1016\/j.therap.2022.01.018_bib0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0379-0738(90)90182-X","article-title":"Post-mortem drug redistribution--a toxicological nightmare","volume":"45","author":"Pounder","year":"1990","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2022.01.018_bib0300","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.forsciint.2012.05.028","article-title":"The time-dependant post-mortem redistribution of antipsychotic drugs","volume":"222","author":"Saar","year":"2012","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2022.01.018_bib0305","doi-asserted-by":"crossref","first-page":"112598","DOI":"10.1016\/j.psychres.2019.112598","article-title":"Antipsychotic drugs and sudden cardiac death: a literature review of the challenges in the prediction, management, and future steps","volume":"281","author":"Zhu","year":"2019","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.therap.2022.01.018_bib0310","series-title":"Th\u00e9saurus des interactions m\u00e9dicamenteuses - ANSM","year":"2021"},{"key":"10.1016\/j.therap.2022.01.018_bib0315","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/FTD.0b013e3181fa57fe","article-title":"Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study","volume":"32","author":"Lancelin","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2022.01.018_bib0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1163\/156856295X00391","article-title":"Disposable devices for the dispensing of oral drops. Study of photoprotectiveness and compatibility","volume":"7","author":"Airaudo","year":"1995","journal-title":"J Biomater Sci Polym Ed"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:27Z","timestamp":1758567327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0040595722000294"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.01.018","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suivi th\u00e9rapeutique pharmacologique de la cyam\u00e9mazine\u00a0: comment interpr\u00e9ter une concentration\u00a0? Une revue de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}